Asparlas and Ethinyl estradiol and norelgestromin transdermal
Determining the interaction of Asparlas and Ethinyl estradiol and norelgestromin transdermal and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance. MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Professional:GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.
MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Generic Name: ethinyl estradiol / norelgestromin
Brand name: Xulane, Ortho Evra
Synonyms: Ethinyl estradiol and norelgestromin (transdermal), Ethinyl Estradiol and Norelgestromin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Asparlas-Ethinyl estradiol and norethindrone
- Asparlas-Ethinyl estradiol and norethindrone birth control
- Asparlas-Ethinyl Estradiol and Norethindrone Chewable Tabs & Ferrous Fumarate Tabs
- Asparlas-Ethinyl estradiol and norethindrone HRT
- Asparlas-Ethinyl Estradiol and Norethindrone Tablets
- Asparlas-Ethinyl estradiol and norgestimate
- Ethinyl estradiol and norelgestromin transdermal-Aspercreme Lidocaine
- Ethinyl estradiol and norelgestromin transdermal-Aspergum
- Ethinyl estradiol and norelgestromin transdermal-Aspir 81
- Ethinyl estradiol and norelgestromin transdermal-Aspir-Low
- Ethinyl estradiol and norelgestromin transdermal-Aspirin
- Ethinyl estradiol and norelgestromin transdermal-Aspirin and caffeine